<DOC>
	<DOCNO>NCT02992132</DOCNO>
	<brief_summary>To evaluate efficacy pimavanserin compare placebo treatment agitation aggression 12 week treatment</brief_summary>
	<brief_title>Study Examine Safety Efficacy Pimavanserin Treatment Agitation Aggression Alzheimer 's Disease ( SERENE )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>1 . Male female , 50 year age old 2 . Must able understand provide sign informed consent patient , capable give consent patient 's Legally Authorized Representative ( LAR ) patient capable give consent . 3 . Has diagnosis probable AD accord National Institute AgingAlzheimer 's Association ( NIAAA ) guideline 4 . Meets criteria agitation accord International Psychogeriatric Association ( IPA ) guideline 5 . Lives home assist living facility ( visit clinic outpatient ) . Subjects must current location least 3 week prior Screening plan remain location duration trial . 6 . Has designate study partner/caregiver contact patient least 3 time week 3 separate day 7 . Female patient must nonchildbearing potential must agree use acceptable method contraception abstinence , least 1 month prior randomization , study , 1 month follow completion study 8 . The patient caregiver willing able participate schedule evaluation complete require test 1 . The agitation/aggression attributable concomitant medication , environmental condition , substance abuse , active medical psychiatric condition 2 . Treatment antipsychotic medication within 2 week Baseline visit 5 half life , whichever longer 3 . Patient study partner/caregiver medical condition ( e.g. , hearing , vision impairment ) would impair ability perform study assessment . 4 . Has myocardial infarction within last six month 5 . Has history symptom long QT syndrome 6 . Has history significant psychotic disorder diagnosis probable Alzheimer 's disease ( include , limited schizophrenia bipolar disorder ) 7 . Patient bedridden significant medical condition unstable would place patient undue risk study drug study procedure Has sensitivity pimavanserin excipients 8 . Has previously participate clinical study pimavanserin</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>